Topic

Tumor Mutational Burden (TMB)

  • Pan-tumor biomarkers are key to some of today’s most remarkable cancer breakthroughs. One such biomarker is microsatellite instability (MSI), which plays an important role in immunotherapy treatment for advanced colorectal cancer patients. In the last four years, for example, the FDA approved two …

    Continue Reading

  • Setting the Pace for Blood Tumor Mutational Burden

    New biomarkers for cancer immunotherapy have taken center stage at major oncology meetings recently, mostly notably the genomic biomarker tumor mutational burden (TMB). Multiple clinical trial results support TMB’s potential in identifying patients most likely to benefit from immunotherapy across a wide range of tumor …

    Continue Reading

  • Approximately 15 percent of all colorectal cancers (CRCs) are genetically defined as microsatellite instability (MSI) high.1 This means that the DNA repair mechanisms in the tumor cells are faulty, and as a result, they can acquire a significant number of mutations that can make them easily recognizable by the immune …

    Continue Reading

  • Quantum Leaps for Quantitative Markers

    Recent clinical data demonstrate the enormous impact that quantitative genomic biomarkers like tumor mutational burden (TMB) have made on the treatment landscape, especially in immunotherapy. TMB was a major topic at the recent American Association for Cancer Research (AACR) Annual Meeting, standing alongside data …

    Continue Reading

  • The Future of Personalized Cancer Care is Now

    Cancer immunotherapy has revolutionized how we view cancer treatment. When it works, the results are transformative. But right now, only a subset of people treated with immunotherapies respond. The ability to reliably identify both responders and non-responders to immunotherapy is one of the most important …

    Continue Reading

  • Tumor Mutational Burden (TMB) Could Help Predict Response to Immunotherapy

    Tumor mutational burden (TMB) is a genomic biomarker with the potential to make a significant impact on the landscape of cancer immunotherapy. This emerging marker measures the number of mutations within a tumor genome and has already been shown to be associated with improved responses to checkpoint inhibitor …

    Continue Reading

  • Completing the Puzzle for Colorectal Cancer

    Each person and each cancer is unique, and the goal of precision medicine is to uncover this individuality. For colorectal cancer (CRC), we have discovered a few important pieces of the puzzle, but the entire picture is incomplete. There is an urgent need to discover more specific predictive markers of CRC that can …

    Continue Reading

  • Over 144,000 Americans are expected to be diagnosed with melanoma this year.1 With a 15-20% 5-year survival rate for Stage IV patients, the future is not always optimistic.2 Thankfully, immunotherapy is changing that outlook. For example, one recent study found that an anti-PD-1 therapy doubled the survival rate in …

    Continue Reading

  • Tumor Mutational Burden: A Valuable Addition to the Pathologist’s Toolbox

    We picture pathologists behind the scenes, facing a microscope in a lab rather than a patient in a clinic. Although most patients may never even meet one, there may be no specialist more important to ensuring that the cancer treatment team delivers an effective regimen. For generations, pathologists’ keen eyes and …

    Continue Reading

  • Today, Foundation Medicine and our collaborators presented data at the American Society of Clinical Oncology (ASCO) annual meeting demonstrating that tumor mutational burden (TMB) measured by FoundationOne comprehensive genomic profiling (CGP) is a potentially more sensitive method for identifying responders to …

    Continue Reading

  • Cancer immunotherapies are revolutionizing the world of oncology. This exciting new class of medicines retrains the body’s own immune system to fight cancer. Unlike cytotoxic chemotherapy, the immune system is “smart” and can adapt and evolve with the cancer over time – potentially resulting in unprecedented long-term …

    Continue Reading